# Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis

> **NCT01470053** · PHASE3 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 347 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** mometasone furoate plus azelastine HCl
- **DRUG:** mometasone furoate
- **DRUG:** azelastine HCl

## Key facts

- **NCT ID:** NCT01470053
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-12
- **Final completion:** 2012-11
- **Target enrollment:** 347 (ACTUAL)
- **Last updated:** 2013-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470053, "Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01470053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*